Table 3.
Averaged changes in parameters of sigmoidal baroreflex functions for RSNA and pre-ASNA measured before vs. after microinjections into the NTS of A2a adenosine receptor agonist (CGS-21680), adenosine receptor antagonists (ZM-241385 and 8-SPT), and respective volume controls (ACF)
| ACF 50 (n = 8) | CGS 2.0 (n = 9) | CGS 20 (n = 8) | ACF 100 (n = 9) | ZM (n = 9) | 8-SPT (n = 9) | |
|---|---|---|---|---|---|---|
| BP50, mmHg | ||||||
| RSNA | 3.3±2.4 | −2.0±1.8 | 4.8±2.2 | 1.4±2.3 | 1.5±1.5 | −1.5±2.1 |
| PreASNA | 0.5±2.7 | −1.0±0.8 | 6.8±2.2 | 0.9±1.8 | 2.8±1.4 | 1.0±1.3 |
| Upper plateau, % | ||||||
| RSNA | −17.5±13.6 | −51.0±5.3* | −63.8±7.5* | −11.2±11.8 | 15.7±9.2 | 8.3±7.8 |
| PreASNA | 10.3±7.7 | 17.3±21.3† | 51.6±12.0*† | −0.9±5.6 | 4.0±14.8 | −3.0±7.6 |
| Lower plateau, % | ||||||
| RSNA | −2.0±3.6 | −5.1±2.6 | −4.8±3.2 | −0.4±3.2 | −1.7±0.7 | 0.5±2.7 |
| PreASNA | 0.3±1.3 | −2.0±3.2 | 9.7±3.5*† | −8.9±5.4 | −4.3±1.7 | −1.5±1.7 |
Data are means ± SE. The responses to CGS-21680 were compared with respective volume control of 50 nl of ACF, and the responses to ZM-241385 and 8-SPT were compared with respective volume control of 100 nl of ACF.
*
Significnat difference vs. ACF (P < 0.05).
†
Significant difference vs. RSNA (P < 0.05).